cyrilzakka/clinical-trials huggingface dataset:
Lifestyle Practices With Chronic Diseases Among Different Professionals

A qualitative study conducted in 2018 Exploring socio-cultural factors impacting adherence to type 2 diabetes therapy in rural Sargodha featured respondents who were primarily doctors, patients, and. Diet, exercise, and smoking were all variables. The void we investigators will fill will be comprised of several professionals assessing sleep and sedentary lifestyle. A book on anthropology published in 2021 shows the gap are still the same about sedentary life style.

The investigators aim to determine lifestyle practices in relation to sedentary behaviour in different occupations \& comparing which profession is prone to chronic diseases in accordance to lifestyle practices

Considering all the numerous variables that can have an effect on someone's health, it seems obvious that prior research into all the potential determinants of a health intervention's success is necessary. Care for a sickness requires knowledge of both the disease itself and the patient's social and cultural context, thus it's important to learn about both. Since diabetes is chronic, it must be managed permanently. IDF's most recent projections for 2019 show that the prevalence of diabetes in Pakistan has risen dramatically. There will be 33 million diabetic adults in Pakistan in 2021, a 70% rise from 2019. After China (with 141 million cases) and India (with 102 million), Pakistan presently has the third-highest rate of diabetes prevalence worldwide (74 million). The growth in the prevalence of type 2 diabetes can be attributed to multiple variables, including but not limited to those in the areas of economics, demography, ecology, and heredity. Urbanization, an ageing population, a decline in physical activity, and a rise in overweight and obesity are all contributing factors.

In addition to providing useful information for larger-scale diabetes initiatives at the national and provincial levels (and their partners), this study's unique emphasis on the patient's point of view could be seen as groundbreaking (as an illness). The recommended treatment will be interpreted from patient's viewpoint and their respective issues, concerns, challenges and socio-cultural elements at large that may influence or compromise the adherence towards the proposed treatment of diabetes. Therefore, from the patient's vantage point, the proposed treatment's implementation through pilot intervention in chosen health facilities can be understood as an explanatory model of sickness (of/for diabetes).

Eligibility Criteria:
Inclusion Criteria:

* People between the ages of 30 and 50
* Sedentary professions, such as teachers and bankers, IT experts, doctors, administrative job personal
* Working for the past 03 years .

Exclusion Criteria:

* Disabled people who cannot move or engage in an active lifestyle .
* Those individuals already diagnosed with mental health issues
Effect of Sedative Agent on Reducing the Frequency of Arrhythmia in the Patients After Cardiac Surgery

Arrhythmias early in the recovery period after cardio thoracic surgery are common they develop in 11 to 40 percent of patients after coronary-artery bypass grafting. The right chose of sedative agent could decrease the level of arrhythmia incidence.

Arrhythmias are really common in patients after cardiac surgery. Most of the patients get sedation after cardiac surgery. The goal is to determine if the propofol (PR) (sedative agent), dexmedetomidine (DEX)(selective α2-adrenergic receptor (α2-AR) agonist) or their combination could improve and decrease the incidence of the arrhythmia in patients after cardiac surgery.

Eligibility Criteria:
Inclusion Criteria:

* Multi vascular lesions of the coronary arteries according to coronary angiography;
* Heart valve damage was confirmed by heart ultrasound, which is subject to surgical correction (aortic stenosis of III degree with a gradient on the aortic valve of more than 42 mmHg, aortic insufficiency III, mitral valve stenosis II-III, mitral regurgitation II-III)
* Age of patients from 18-80 years;

Exclusion Criteria:

* Refusal to participate;
* Hypersensitivity to propofol, dexmedetomidine;
* Acute renal failure that occurred during surgery (ClCr less than 50 ml / h, or a decrease in the rate of diuresis to 0.1 ml / h in the first 4 hours after surgery and does not respond to diuretic therapy)
Diabetes Mellitus Type II and Tissue Oxygenation

The purpose of this study is to determine whether diabetics have decreased amounts of oxygen in the skin compared to non-diabetic individuals, and if the amount of oxygen in the skin changes when given more oxygen to breathe around the time of surgery. To do this, the investigators will be measuring the amount of oxygen in the skin of diabetic and non-diabetic individuals who will be undergoing abdominal surgery lasting 2-4 hours. These measurements will be taken at three different times.

The goal is to test the hypothesis that: 1) perioperative subcutaneous oxygenation (PsqO2) is lower in diabetic than non-diabetic patients; and, 2) supplemental oxygen provides less benefit in diabetic than non-diabetic patients.

We propose a prospective case-control study which will include 30 Type II diabetics matched for age, sex, and race to 30 non-diabetic controls. Patients will be preselected from a population undergoing abdominal surgery and given supplemental inspired oxygen of 30 - 80% to PaO2 of approximately 150mmHg and/or 300mmHg at three timepoints in the perioperative period. PsqO2 will be measured with an IV-sized probe inserted through a small incision made in the skin. Data will be recorded and analyzed using unpaired two tailed t-test, Wilcoxon's ranked sum test, or repeated-measures analysis of variance (ANOVA) test as appropriate.

Eligibility Criteria:
Inclusion criteria:

We will include 30 patients who have more than a five-year history of insulin-dependent type-2 diabetes mellitus and 30 non-diabetic patients meeting the following criteria:

* 35 - 65 yrs old
* BMI \< 30
* ASA class I - III
* Abdominal surgery scheduled to last between 2- 4 hours

For Non-diabetic group:

previous BMP within the last year demonstrating glucose \< 126mg/dL

For Diabetic group:

* DMII defined as fasting plasma glucose of \> 126 mg/dL at time of diagnosis, now requiring insulin
* At least one diabetes associated vasculopathy: coronary artery disease, diabetic nephropathy, hypertension, diabetic retinopathy, diffuse neuropathy, peripheral vascular disease, or a history of stroke

Exclusion Criteria:

* Pregnant
* Immunocompromised: HIV/AIDS, on immunosuppressant therapy for any reason, or post-organ transplantation.
* Infection or fever, or on glucocorticoids
* Malignancy currently requiring radiation or chemotherapy
* Liver or renal failure
* Pancreatic insufficiency, dysautonomia, thyroid disease, Raynaud's syndrome, pathologic Allen-test, or any coagulopathies
* Respiratory disease affecting ability to reach PaO2 of 300mmHg: COPD, emphysema, cystic fibrosis, asthma, pneumonia, PE
* Smoker within the past 6 months or current alcohol abuse
* Allergy to local anesthetic
* For diabetics: DMI, other specific subtype, and gestational diabetics
* We will also exclude patients with epidural catheter, to avoid the influence of regional anesthesia on tissue oxygenation \[37, 38\].
Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies

The purpose of this study is to identify the barriers, and the extent of said barriers, to genomic testing for breast cancer patients among low-income and minority populations, particularly throughout Northern California. The investigators have created a survey that is available online for any patient with cancer to fill out voluntarily regarding their experiences to date. The survey is available at: https://stanforduniversity.qualtrics.com/jfe/form/SV_7VElf8oesWcB3bE

The study has two main data-collecting phases. In phase 1, the investigators will engage multilevel stakeholders to respond to a survey assessing experience with and perceptions of genomic testing and its accessibility for patients with breast cancer in California. In phase 2, selected and interested survey participants who voluntarily provide their contact information on the survey will be asked to participate in an in-depth 1:1 semi-structured interview to explore disparities in genomic testing for breast cancer more closely. The investigators will then utilize their findings from both phases to present aggregate findings to an Expert Panel and Community Advisory Board and work together to develop policy recommendations. The policy recommendations will then be presented to policy makers, with the aim of identifying sustainable solutions that address breast cancer treatment and outcome disparities throughout Northern California.

Eligibility Criteria:
Inclusion Criteria:

* The patients must be 18 years or older.
* Patients who opt in to complete the survey.
* Patients must have the capacity to verbally consent for the interview.

Exclusion Criteria:

* Patients who under the age of 18 years old.
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa


Eligibility Criteria:
Inclusion Criteria:

* Must have a clinical diagnosis of Schizophrenia
* Must be at least 18 years of age and not older than 55 years of age
* Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
* Women of childbearing potential must be using a medically accepted means of contraception
* Must be able to swallow capsules

Exclusion Criteria:

* Has serious health problems other than Schizophrenia
* Takes an antidepressant for depression
* Takes insulin for diabetes
* Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months
Free Time For Wellness 2+

Physical inactivity is pervasive and prevalent in the United States, particularly among women of low socioeconomic position, and women with children. Structural and social barriers make active leisure time a rare commodity creating a pressing health issue because physical inactivity increases the risk of chronic diseases and poor health. The broad objective of this study is to test the effectiveness of Free Time for Wellness (FT4W), an innovative multilevel physical activity intervention to increase physical activity among low-resourced mothers.

Physical inactivity is particularly prevalent in women of low socioeconomic position (SEP) (60% are inactive), suggesting that there are structural barriers to being physically active. This study will test the effectiveness of an intervention to increase physical activity among mothers of low SEP, where there is high risk of chronic disease and significant potential to make an impact on these health disparities.

This study comprises a 3-arm parallel cluster randomized controlled trial with low-resourced mothers living in New York City. The study team will randomize fitness class sites (clusters) into Arm A (contact control), receipt of free weekly fitness classes; Arm B, receipt of free childcare combined with free weekly fitness classes; and Arm C, receipt of free childcare combined with free weekly fitness classes and, plus peer support activities. Over two years the study team will recruit eight waves totaling 630 participants into 21 fitness classes. Physical activity is the primary outcome measured using accelerometers, a self-reported questionnaire, and attendance data. Secondary outcomes (e.g., health status) and mediators/moderators (e.g., social support and cohesion) will be assessed with a baseline and follow-up questionnaire. Ethnographic methods will be used to examine how intersecting forms of social inequality shape women's experiences of physical activity and to understand how real-world conditions shape the intervention implementation. The intention-to-treat analysis will employ linear mixed-effects models (LMM) to assess the main intervention effects on physical activity outcomes and other secondary outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Understand/speak English or Spanish, Have children \<12 years old, Own a mobile phone, Live in the zip code surrounding as Shape Up NYC sites

Exclusion Criteria:

* Total household income being greater than 165% of the area median income (calculated by household size).
Hyperhydrosis Treatment Using Botulinum Toxin

The purpose of this study is to describe two safe and reproducible techniques for the treatment of hyperhidrosis using botulinum toxin. The same patient will receive two different injection technique in each armpit and will be evaluated subjectively and objectively.

The abobotulinumtoxinA (ABO) will be used in all patients. The ABO will be prepared by adding 4 cc of normal saline to a 500-unit Dysport© (Ipsen Ltd, Berks, UK) vial Preinjection patient pictures will be taken showing the technique used for each armpit.

Injection technique:

1. Technique 1 The Quadrant technique: 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
2. Technique 2 the six injection technique: will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units

Follow up will be done at 15 days for post injection pictures with iodine starch test A total of 15 male patients will be recruited. And the injection for each armpit in a given patient is randomized.

Eligibility Criteria:
Inclusion Criteria:

Consecutive 15 male patients presenting to our clinic for primary localized hyperhidrosis will be included in this study

Exclusion Criteria:

* Patient that has received a botulinum injection in the past year

Patient that had a liposuction in the armpit or laser for the hair

Patients with preexisting neuromuscular conditions (myasthenia gravis, Eaton Lambert syndrome) Patients using medication that could potentiate the effect of botulinum (ex: aminoglycoside antibiotics) Patients with sensitivity to botulinum toxin or human albumin
Evaluation of Effectiveness and Safety of the GENOUS STENT (IRIS-GENOUS STEMI)

The objective of this study is to evaluate effectiveness and safety of GENOUS EPC-coated stent in patients with STEMI with other drug-eluting stents (DESs).

This study is a non-randomized, prospective, open-label registry to compare the efficacy and safety of GENOUS stent in STEMI patients with other-type DESs.

Eligibility Criteria:
Inclusion Criteria:

* STEMI Patients requiring primary PCI.
* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site

Exclusion Criteria:

* Patients with a mixture of other DESs
* Terminal illness with life expectancy \<1 year
* Patients with cardiogenic shock
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms


Eligibility Criteria:
Inclusion Criteria:

1. Male or female patient fulfilling the Rome III criteria for IBS-C
2. Signed informed consent at screening visit

Exclusion Criteria:

1. Patients having significant diarrhea at least 25% of the time during the past 3 months
2. Patients having alarm symptoms or signs
3. Chronic diarrhea
4. History of gastrointestinal haemorrhage, mechanical obstruction or perforation
5. Patient with clinically relevant ECG abnormalities (prolonged QT interval)
6. Active psychiatric disorder that would interfere with the study objectives
7. Health conditions (e.g. age related impairment of cognitive functions) that would interfere with the study objectives or might impair the compliance of the patient
8. Severe hepatic, renal, cardiac, metabolic, haematological or malignant diseases (including prolactin dependent tumours) or clinically relevant deviations in laboratory values (AST/ALT greater than twice the upper limit of normal, serum creatinine \* 2 mg/dl \[177 µmol/l\] according to the medical judgement of the investigator
9. Patient with hypokalemia (serum potassium \< 3.5 mmol/l).
10. History of any known hypersensitivity to the ingredients of the investigational drug
11. Pregnancy or lactation
12. Women with childbearing potential who do not apply a medically accepted method of contraception.
Single Versus Multiple Injection Ultrasound Guided Paravertebral Blocks

Paravertebral block (PVB) has been shown to provide excellent analgesia for major breast surgeries resulting in reduced narcotic consumption, reduced nausea, improved quality of recovery, reduced chronic pain and possibly reduced metastasis with breast cancer. Traditionally, PVB is done by multiple injections below T1-T5 transverse processes. With multiple injections, the risk is increased for a pleural, an intraneural, and/or an intravascular injection. Recently, ultrasonography is being used to facilitate PVB. The use of ultrasound imaging enables real-time needle visualization during the procedure. This may improve efficacy and reduce the chances of complication like pneumothorax. Currently, there are no data comparing ultrasound-guided single injection technique with multiple injections technique with regards to extent of spread for PVB. Our objective is to investigate the extent of dermatomal spread of PVB when equal volumes of local anesthetic are injected at one versus five paravertebral sites for patients undergoing major breast surgery. In addition, the investigators wish to compare the performance time and duration of analgesia.

Methodology: After local REB approval, 72 patients undergoing a unilateral mastectomy with or without axillary node dissection will be randomized to receive either single or multiple injections PVB. The PVB will be performed in prone position under real-time ultrasound guidance using a para-sagittal approach.The patients in single injection group will receive single injection PVB at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections. Patients in the multiple injection group will receive five injections of PVB from T1 to T5 level. 5 ml of 0.5% ropivacaine will be injected at each level. Pleural drift will be used as a sign of correct needle tip location and local anaesthetic spread. The pinprick method will be used to assess the extent of dermatomal blockade, 20 minutes following the completion of procedure. All patients will receive a standardized general anesthesia for the surgery. Any adverse events including pneumothorax, epidural spread, LA toxicity/seizure, total spinal, will be recorded.


Eligibility Criteria:
Inclusion Criteria:

* Females, age 18 to 80 years, scheduled to receive unilateral mastectomy surgery, with or without axillary node dissection
* Able to give informed consent
* Able to cooperate with study process
* Availability of home telephone.

Exclusion Criteria:

* Patient refusal or lack of informed consent
* allergy to local anesthetic and other medications used in the study
* Bilateral mastectomies
* Coexisting hematological disorder or with deranged coagulation parameters
* Pre-existing major organ dysfunction such as hepatic and renal failure
* Significant thoracic kyphoscoliosis
* History of previous thoracic surgery.
Phototherapy in Association to Resistance Training in the Elderly: the Effect on Muscle Strength, Muscle Mass and Functional Capacity

Phototherapy has been largely used in rehabilitation programs due to its analgesic, antiinflammatory and healing effects. Lately, its effects of optimizing the results of resistance training on young individuals have been studied. However, there is a lack of studies on its effect on the elderly population. The objective of the present study is to verify the effect of Low-Level Laser Therapy (LLLT) on the results of resistance training in the elderly. The study will be a randomized doubled-blinded controlled trial. 30 elderly men with age ranging from 60 to 80 years will be included and randomized between Placebo Group (placebo LLLT + Resistance Training) and LLLT Group (active LLLT + Resistance Training). All volunteers will be submitted to a control period of four weeks before the beginning of the resistance training, which will have 12 weeks of duration. The assessments will be done at baseline, after the control period and after the training period. The training sessions will be performed twice a week and the training protocol will be performed with repetition maximum periodization. The LLLT will be applied before the training sessions on eight points of the quadriceps muscles, leading to a total of 240 Joules on each leg. The placebo LLLT will be applied on the same way, but with the equipment turned off. The assessments will include muscle architecture by ultrasonography, muscle strength by isokinetic dynamometer and 1 Repetition Maximum test of leg-extension and leg-press exercises, and functional capacity by the 6-Minute Walking Test, 30s Sit to Stand Test, Timed Up-and-Go Test and Stair Ascent Test.


Eligibility Criteria:
Inclusion Criteria:

* Elderly men with age ranging from 60 to 80 years in condition to participate in the strength training program.

Exclusion Criteria:

* Individuals who already participate in strength training programs;
* Individuals who participated in strength training programs less than three months before the beginning of the study;
* Individuals with any kind musculoskeletal injuries in the lower limbs that impair the performance of the exercises;
* Individuals with contraindications to the performance of high intensity exercises, such as cardiovascular or neurological diseases;
* Individuals with difficulties in understanding and/or performing the exercises;
* Individuals who did not attend to at least 85% of the sessions or had 02 consecutive absences and did not recover them.
Hop Compounds and Immune System

The aim of the present study is to determine the effect of Xanthohumol and Iso-alpha-acids from hops on the immune response of healthy participants.

In this placebo-controlled crossover study a study drink enriched with either a placebo, Xanthohumol, Iso-alpha Acids or a combination of latter is given to the participants. A washout phase before intervention and between each intervention is introduced. On day one of each intervention blood is drawn in fasted state from each participant. Subsequently the study drink combined with a standardized breakfast is given to the participants following a second blood drawing one hour after the consumption of the study drink. On the last day of each intervention blood is taken from study participants in the same manner as on day one. To assess the effect of Xanthohumol and Iso-alpha acids or a combination of both, clinical chemical parameters e.g. ALT, AST, γ-GT, blood lipids (triglycerides, total cholesterol, HDL, LDL), blood glucose, uric acid and CRP are determined. Furthermore, PBMC's isolated from blood samples of each time point were stimulated for either 24 or 48 h. Protein levels and mRNA expression of markers of inflammation is measured in PBMC's and supernatant of stimulated cells.

Eligibility Criteria:
Inclusion Criteria:

* healthy, normal weight,

Exclusion Criteria:

* food intolerances, food allergies, chronic inflammatory diseases, metabolic diseases, viral or bacterial infections within the last 3 weeks of inclusion, intake of immunosupressive medication